Last reviewed · How we verify
IMIDAPRIL
Imidapril is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established presence in the market, leveraging its current revenue streams. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | IMIDAPRIL |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics (PHASE4)
- Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria (PHASE3)
- Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD) (PHASE2)
- Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMIDAPRIL CI brief — competitive landscape report
- IMIDAPRIL updates RSS · CI watch RSS